thalidomide has been researched along with Cardiac Failure in 25 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has recently shown to improve LVEF in chronic heart failure patients, accompanied by a marked decrease in plasma levels of tumor necrosis factor alpha (TNF-alpha)." | 9.12 | Effects of thalidomide treatment in heart failure patients. ( Arrieta-Rodríguez, O; Asensio-Lafuente, E; Castillo-Martínez, L; Dorantes-García, J; Granados-Arriola, J; Orea-Tejeda, A; Rodríguez-Reyna, T, 2007) |
| "Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD)." | 9.11 | Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. ( Andreassen, A; Aukrust, P; Breivik, K; Fjeld, JG; Frøland, SS; Følling, M; Gullestad, L; Gundersen, T; Hodt, A; Holt, E; Kjekshus, E; Kjekshus, J; Semb, AG; Skårdal, R; Ueland, T; Wergeland, R; Yndestad, A, 2005) |
| "Thalidomide was assessed in preclinical and clinical studies." | 6.70 | Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. ( Agoston, I; Bozkurt, B; Dibbs, ZI; Mann, DL; Muller, G; Wang, F; Zeldis, JB, 2002) |
| "NYHA cardiac failure staging was the only independent factor affecting overall survival." | 5.43 | Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. ( Avivi, I; Ballan-Haj, M; Chubar, E; Cohen, Y; Dally, N; Gatt, ME; Hardan, I; Jakubinsky, J; Magen, H; Muchtar, E; Patachenco, P; Shevetz, O; Suriu, C; Tadmor, T; Trestman, S; Yeganeh, S, 2016) |
| " Thalidomide has recently shown to improve LVEF in chronic heart failure patients, accompanied by a marked decrease in plasma levels of tumor necrosis factor alpha (TNF-alpha)." | 5.12 | Effects of thalidomide treatment in heart failure patients. ( Arrieta-Rodríguez, O; Asensio-Lafuente, E; Castillo-Martínez, L; Dorantes-García, J; Granados-Arriola, J; Orea-Tejeda, A; Rodríguez-Reyna, T, 2007) |
| "Inflammation and matrix degradation may play a pathogenic role in chronic heart failure (CHF), and therefore, we examined whether thalidomide, a drug with potential immunomodulating and matrix-stabilizing properties, could improve left ventricular (LV) function in patients with CHF secondary to idiopathic dilated cardiomyopathy (IDCM) or coronary artery disease (CAD)." | 5.11 | Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. ( Andreassen, A; Aukrust, P; Breivik, K; Fjeld, JG; Frøland, SS; Følling, M; Gullestad, L; Gundersen, T; Hodt, A; Holt, E; Kjekshus, E; Kjekshus, J; Semb, AG; Skårdal, R; Ueland, T; Wergeland, R; Yndestad, A, 2005) |
| "Thalidomide was assessed in preclinical and clinical studies." | 2.70 | Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. ( Agoston, I; Bozkurt, B; Dibbs, ZI; Mann, DL; Muller, G; Wang, F; Zeldis, JB, 2002) |
| "Thalidomide is an anti-angiogenic compound that may offer a potential option for management of refractory LVAD-related GIB." | 1.46 | Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients. ( Chan, LL; Kerk, KL; Lim, CP; Seng, BJJ; Sim, DKL; Sivathasan, C; Soon, JL; Tan, TE; Teo, LLY, 2017) |
| "NYHA cardiac failure staging was the only independent factor affecting overall survival." | 1.43 | Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. ( Avivi, I; Ballan-Haj, M; Chubar, E; Cohen, Y; Dally, N; Gatt, ME; Hardan, I; Jakubinsky, J; Magen, H; Muchtar, E; Patachenco, P; Shevetz, O; Suriu, C; Tadmor, T; Trestman, S; Yeganeh, S, 2016) |
| "Echocardiography detected left ventricular hypertrophy and diastolic dysfunction." | 1.39 | Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome. ( Hisa, S; Kanno, Y; Kobayashi, A; Mizukami, H; Nakazato, K; Noji, H; Ogawa, K; Ohkawara, H; Saitoh, S; Shichishima-Nakamura, A; Suzuki, H; Takahashi, H; Takeishi, Y; Yokokawa, T; Yoshihisa, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 13 (52.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Namdaran, P | 1 |
| Zikos, TA | 1 |
| Pan, JY | 1 |
| Banerjee, D | 2 |
| Seng, BJJ | 1 |
| Teo, LLY | 1 |
| Chan, LL | 1 |
| Sim, DKL | 1 |
| Kerk, KL | 1 |
| Soon, JL | 1 |
| Tan, TE | 1 |
| Sivathasan, C | 1 |
| Lim, CP | 1 |
| Imamura, T | 1 |
| Kinugawa, K | 1 |
| Uriel, N | 1 |
| Arnall, JR | 1 |
| Usmani, SZ | 1 |
| Adamu, H | 1 |
| Mishkin, J | 1 |
| Bhutani, M | 1 |
| Tokuyama, M | 1 |
| Shimizu, T | 1 |
| Yamada, T | 1 |
| Kondoh, A | 1 |
| Mabuchi, T | 1 |
| Yokokawa, T | 1 |
| Nakazato, K | 1 |
| Kanno, Y | 1 |
| Mizukami, H | 1 |
| Kobayashi, A | 1 |
| Yoshihisa, A | 1 |
| Takahashi, H | 1 |
| Shichishima-Nakamura, A | 1 |
| Ohkawara, H | 1 |
| Noji, H | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Ogawa, K | 1 |
| Hisa, S | 1 |
| Takeishi, Y | 1 |
| Draper, K | 1 |
| Kale, P | 1 |
| Martin, B | 1 |
| Kelly Cordero, R | 1 |
| Ha, R | 1 |
| Mann, DL | 3 |
| Gatt, ME | 1 |
| Hardan, I | 1 |
| Chubar, E | 1 |
| Suriu, C | 1 |
| Tadmor, T | 1 |
| Shevetz, O | 1 |
| Patachenco, P | 1 |
| Dally, N | 1 |
| Yeganeh, S | 1 |
| Ballan-Haj, M | 1 |
| Cohen, Y | 1 |
| Trestman, S | 1 |
| Muchtar, E | 1 |
| Magen, H | 1 |
| Jakubinsky, J | 1 |
| Avivi, I | 1 |
| Palladini, G | 1 |
| Russo, P | 1 |
| Lavatelli, F | 1 |
| Nuvolone, M | 1 |
| Albertini, R | 1 |
| Bosoni, T | 1 |
| Perfetti, V | 1 |
| Obici, L | 1 |
| Perlini, S | 1 |
| Moratti, R | 1 |
| Merlini, G | 1 |
| Blum, A | 1 |
| Inoue, D | 1 |
| Kato, A | 1 |
| Tabata, S | 1 |
| Kitai, T | 1 |
| Takiuchi, Y | 1 |
| Kimura, T | 1 |
| Shimoji, S | 1 |
| Mori, M | 1 |
| Nagai, Y | 1 |
| Togami, K | 1 |
| Matsushita, A | 1 |
| Nagai, K | 1 |
| Maruoka, H | 1 |
| Imai, Y | 1 |
| Beppu, M | 1 |
| Kawamoto, M | 1 |
| Takahashi, T | 1 |
| Tageja, N | 1 |
| Dispenzieri, A | 1 |
| Dingli, D | 1 |
| Kumar, SK | 1 |
| Rajkumar, SV | 1 |
| Lacy, MQ | 1 |
| Hayman, S | 1 |
| Buadi, F | 1 |
| Zeldenrust, S | 1 |
| Leung, N | 1 |
| Detweiler-Short, K | 1 |
| Lust, JA | 1 |
| Russell, SJ | 1 |
| Kyle, RA | 1 |
| Gertz, MA | 1 |
| Falk, RH | 1 |
| Gadó, K | 1 |
| Domján, G | 1 |
| Vescovo, G | 1 |
| Ravara, B | 1 |
| Angelini, A | 1 |
| Sandri, M | 1 |
| Carraro, U | 1 |
| Ceconi, C | 1 |
| Dalla Libera, L | 1 |
| Agoston, I | 1 |
| Dibbs, ZI | 1 |
| Wang, F | 1 |
| Muller, G | 1 |
| Zeldis, JB | 1 |
| Bozkurt, B | 1 |
| Gullestad, L | 3 |
| Semb, AG | 2 |
| Holt, E | 2 |
| Skårdal, R | 2 |
| Ueland, T | 3 |
| Yndestad, A | 3 |
| Frøland, SS | 2 |
| Aukrust, P | 3 |
| Fjeld, JG | 1 |
| Gundersen, T | 1 |
| Breivik, K | 1 |
| Følling, M | 1 |
| Hodt, A | 1 |
| Kjekshus, J | 1 |
| Andreassen, A | 1 |
| Kjekshus, E | 1 |
| Wergeland, R | 1 |
| Damås, JK | 1 |
| Orea-Tejeda, A | 1 |
| Arrieta-Rodríguez, O | 1 |
| Castillo-Martínez, L | 1 |
| Rodríguez-Reyna, T | 1 |
| Asensio-Lafuente, E | 1 |
| Granados-Arriola, J | 1 |
| Dorantes-García, J | 1 |
| McGowan, N | 1 |
| Davey, PP | 1 |
| Ashrafian, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.[NCT01510613] | Phase 2 | 28 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| GutHeart: Targeting Gut Microbiota to Treat Heart Failure[NCT02637167] | Phase 2 | 150 participants (Anticipated) | Interventional | 2016-03-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for thalidomide and Cardiac Failure
| Article | Year |
|---|---|
Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device.
Topics: Anticoagulants; Blood Component Transfusion; Fish Oils; Gastrointestinal Hemorrhage; Heart Failure; | 2018 |
Innate immunity and the failing heart: the cytokine hypothesis revisited.
Topics: Adaptive Immunity; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Autoantibodies; Autoim | 2015 |
Immunological mediated therapies for heart failure.
Topics: Heart Failure; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosorbents; Immunosupp | 2009 |
[AL amyloidosis].
Topics: Algorithms; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2012 |
Inflammatory mediators and the failing heart: past, present, and the foreseeable future.
Topics: Animals; Antibodies, Monoclonal; Antirheumatic Agents; Clinical Trials as Topic; Cytokines; Disease | 2002 |
Anti-inflammatory trials in chronic heart failure.
Topics: Adult; Aged; Animals; Cytokines; Female; Free Radical Scavengers; Heart Failure; Humans; Immunoglobu | 2006 |
What's wrong with this patient? Primary systemic amyloidosis.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Diagnosis, Differential; Disease Progres | 2006 |
New therapies for heart failure: is thalidomide the answer?
Topics: Heart Failure; Humans; Immunosuppressive Agents; Thalidomide; Tumor Necrosis Factor-alpha | 2000 |
4 trials available for thalidomide and Cardiac Failure
| Article | Year |
|---|---|
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide.
Topics: Aged; Amyloidosis; Dexamethasone; Drug Therapy, Combination; Female; Heart Diseases; Heart Failure; | 2009 |
Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure.
Topics: Adult; Aged; Blood Pressure; Cytokines; Dose-Response Relationship, Drug; Drug Evaluation; Female; H | 2002 |
Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study.
Topics: Aged; Cardiomyopathy, Dilated; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow | 2005 |
Effects of thalidomide treatment in heart failure patients.
Topics: Aged; Biomarkers; Cardiovascular Agents; Female; Heart Failure; Humans; Male; Middle Aged; Prospecti | 2007 |
13 other studies available for thalidomide and Cardiac Failure
| Article | Year |
|---|---|
Thalidomide Use Reduces Risk of Refractory Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices.
Topics: Adult; Aged; Arteriovenous Malformations; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart- | 2020 |
Novel use of low-dose thalidomide in refractory gastrointestinal bleeding in left ventricular assist device patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Heart Failure; Heart-Assi | 2017 |
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Topics: Adult; Antibodies, Monoclonal; Cyclophosphamide; Dexamethasone; Female; Heart Failure; Hematopoietic | 2019 |
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
Topics: Aged; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Creatinine; Electrocardiography; | 2019 |
Pulmonary hypertension and refractory heart failure in a patient with Crow-Fukase (POEMS) syndrome.
Topics: Aged; Dexamethasone; Diuretics; Drug Resistance; Edema; Furosemide; Heart Failure; Humans; Hypertens | 2013 |
Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol.
Topics: Adult; Aged; Angiodysplasia; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Gast | 2015 |
Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
Topics: Aged; Amyloidogenic Proteins; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bortezomi | 2016 |
Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide.
Topics: Anti-Inflammatory Agents; Dexamethasone; Drug Therapy; Drug Therapy, Combination; Female; Heart Fail | 2010 |
POEMS syndrome, congestive heart failure and thalidomide -food for thought.
Topics: Capillary Leak Syndrome; Dexamethasone; Drug Therapy, Combination; Heart Failure; Humans; Inflammati | 2010 |
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Topics: Amyloid; Amyloidosis; Biomarkers; Clinical Trials as Topic; Combined Modality Therapy; Cyclophospham | 2010 |
Cardiac amyloidosis: a treatable disease, often overlooked.
Topics: Adrenergic beta-Antagonists; Amyloidosis; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2011 |
Effect of thalidomide on the skeletal muscle in experimental heart failure.
Topics: Animals; Apoptosis; Heart Failure; Monocrotaline; Muscle, Skeletal; Muscular Atrophy; Myosin Heavy C | 2002 |
Effect of thalidomide in patients with chronic heart failure.
Topics: Aged; Biomarkers; Female; Heart Failure; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; | 2002 |